JAK Inhibitors for Lung Cancer | A Pipeline Analysis Report 2018 | Technavio

Technavio has published a new report on the drug development pipeline for JAK inhibitors for lung cancer, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

LONDON--()--Technavio has announced their latest pipeline analysis report on the JAK inhibitors for lung cancer market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat eosinophilic esophagitis.

This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market during the forecast period.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

JAK inhibitors for lung cancer: Market overview

According to Center for Disease Control (CDC), lung cancer is one of the leading causes of cancer mortality and the second most diagnosed cancer for both men and women in the US. In lung cancer, cancer cells start growing uncontrollably and may even start to spread to the lymph nodes and other parts of the body. Similarly, cancer cells initiated in other parts of the body may also spread to the lungs.

Lung cancer can be classified into two types which are small lung cancer and NSCLC. The activation of Janus Kinase 1 is believed to play a crucial role in the development of oncologic and autoimmune diseases. JAK inhibitors are being developed for treatment of lung cancer.

According to a senior analyst at Technavio for research on infectious and rare diseases, “In the current drug development pipeline, around 67% of the molecules under development are being developed by companies in collaboration with institutions under a partnership program. For instance, INCB39110 is under development by Incyte, AstraZeneca, and the Trustees of the University of Pennsylvania.”

JAK inhibitors for lung cancer: Market segmentation

This market research report segments the JAK inhibitors for lung cancer market based on drugs under development (preclinical, Phase I/II), therapies employed (combination therapy, and monotherapy + combination therapy), RoA (oral and unknown), therapeutic modality (small molecules, and unknown), and geographical coverage. It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Monotherapy includes the use of a single drug to treat a disorder, while combination therapy involves the use of more than one drug to treat a disorder. In the current pipeline, a single molecule that is being investigated is used as both monotherapy and combination therapy. With respect to RoA, nearly 67% of the total therapeutics being developed are for oral administration whereby the drug is administered through the mouth cavity.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age
  • Recruitment volume

Key Companies

  • Type of players
  • Company Overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio has announced their latest pipeline analysis report on the JAK inhibitors for lung cancer market.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200